Detalhe da pesquisa
1.
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
Lancet Neurol
; 22(6): 476-484, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37210098
2.
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
J Antimicrob Chemother
; 67(2): 465-8, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22121190
3.
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV Clin Trials
; 13(3): 119-30, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22592092
4.
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
J Antimicrob Chemother
; 66(2): 363-70, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21148235
5.
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
AIDS Care
; 23(11): 1500-4, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21732894
6.
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
AIDS Care
; 22(6): 677-86, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20467943
7.
96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients.
J Int Assoc Physicians AIDS Care (Chic)
; 9(1): 34-42, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20071596
8.
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Clin Infect Dis
; 48(9): 1323-6, 2009 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19302017
9.
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Lancet
; 372(9639): 646-55, 2008 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-18722869
10.
Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.
Clin Infect Dis
; 37(Suppl 1): S13-24, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12822128
11.
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Clin Drug Investig
; 34(4): 287-96, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24557728
12.
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy.
Antivir Ther
; 19(7): 693-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24739445
13.
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Pharmacotherapy
; 33(3): 284-94, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23456732
14.
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
AIDS Res Hum Retroviruses
; 29(10): 1287-92, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782005
15.
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
AIDS Patient Care STDS
; 26(5): 259-64, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22404426
16.
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
PLoS One
; 5(6): e10952, 2010 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-20532178
17.
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
J Acquir Immune Defic Syndr
; 53(3): 323-32, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20032785
18.
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
J Acquir Immune Defic Syndr
; 51(2): 153-62, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19346966
19.
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
J Acquir Immune Defic Syndr
; 47(2): 161-7, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17971713
20.
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study
Artigo
em Inglês
| Arca: Repositório institucional da Fiocruz | ID: arc-30165